Exploring how a malaria protein contributes to drug resistance.
Understanding Plasmodium falciparum's multidrug resistance protein through the characterization of a novel antimalarial class.
This study is looking at a protein in malaria parasites that helps them resist treatment, and by understanding how changes in this protein work, we hope to find new ways to create better medicines for people fighting malaria.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-11065413 on NIH RePORTER |
What this research studies
This research investigates the role of the PfMDR1 protein in malaria parasites, which is linked to resistance against current antimalarial treatments. By examining how mutations in this protein affect the parasite's ability to resist drugs, the research aims to identify new therapeutic targets and strategies. The approach includes analyzing the protein's function and its interactions with various antimalarial agents. This could lead to the development of more effective treatments for malaria.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in malaria-endemic regions who are infected with Plasmodium falciparum.
Not a fit: Patients who are not infected with malaria or those living in non-endemic regions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antimalarial drugs that are effective against resistant strains of the parasite.
How similar studies have performed: Previous research has shown success in targeting drug resistance mechanisms in other infectious diseases, suggesting potential for similar breakthroughs in malaria treatment.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Bremers, Emily Kara — University of Georgia
- Study coordinator: Bremers, Emily Kara
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.